menu
    • menu

    Company profile for VarmX

    Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.

    Virtual Booth

    Contact Supplier

    With Virupaksha, you get a quality product with on-time delivery.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2025-11-24

    Virtual Booth

    Contact Supplier

    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    ChemExpress delivers end-to-end CRO & CDMO solutions for small molecules, biologics & new modalities with ICH-grade quality.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    VarmX B.V. is manufacturing therapeutic proteins to instantaneously restore blood clotting in bleeding patients. In September 2017, a ground-breaking study was published in Nature Communication (Verhoef et al., 2017) presenting VMX-COO1 as a safe and effective reversal agent for prevention and treatment of bleeding in the presence of FXa-DOACs. The factor Xa from the venom of one of the most venomous snake in the world - the A...
    VarmX B.V. is manufacturing therapeutic proteins to instantaneously restore blood clotting in bleeding patients. In September 2017, a ground-breaking study was published in Nature Communication (Verhoef et al., 2017) presenting VMX-COO1 as a safe and effective reversal agent for prevention and treatment of bleeding in the presence of FXa-DOACs. The factor Xa from the venom of one of the most venomous snake in the world - the Australian brown snake named Pseudonaja textilis - was the source of inspiration for the creation VMX-COO1. Venom factor Xa causes human blood to clot even in the presence of factor Xa inhibitors.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    VarmXNetherlands1 Flag
    Country
    Country
    Netherlands
    Address
    Address
    Middelweg 38 B 2312 KJ Leiden
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.varmx.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    DDL Conference

    Not Confirmed

    envelop Contact Supplier

    DDL Conference

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    VarmX Gets Ph 1 Waiver from PMDA for Lead Asset VMX-C001
    VarmX Gets Ph 1 Waiver from PMDA for Lead Asset VMX-C001

    25 Sep 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/09/25/3155995/0/en/VarmX-receives-Phase-1-waiver-from-Japanese-regulator-PMDA-for-lead-asset-VMX-C001.html

    GLOBENEWSWIRE
    25 Sep 2025
    Share Share
    CSL Invests $117 M for VarmX Acquisition, Coagulation Treatment
    CSL Invests $117 M for VarmX Acquisition, Coagulation Treatment

    17 Sep 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250915030511/en/VarmX-Partners-With-CSL-in-a-Strategic-Collaboration-and-Option-Agreement-to-Develop-Novel-Investigational-Coagulation-Treatment

    BUSINESSWIRE
    17 Sep 2025
    Share Share
    VarmX Announces Appointment of John Glasspool as CEO
    VarmX Announces Appointment of John Glasspool as CEO

    12 Nov 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20241112439907/en

    BUSINESSWIRE
    12 Nov 2024
    Share Share
    VarmX to Attend LSX World Congress and Bio€quity Europe in Q2 2024
    VarmX to Attend LSX World Congress and Bio€quity Europe in Q2 2024

    28 Mar 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240328882295/en

    BUSINESSWIRE
    28 Mar 2024
    Share Share
    VarmX Promotes CSO Dr. Jeffrey Lawson to New CEO
    VarmX Promotes CSO Dr. Jeffrey Lawson to New CEO

    12 Oct 2023

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20231012137202/en

    BUSINESSWIRE
    12 Oct 2023
    Share Share
    VarmX Raises €30 Million Series B2 Financing for IND Approval
    VarmX Raises €30 Million Series B2 Financing for IND Approval

    25 May 2023

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20230525005127/en

    BUSINESSWIRE
    25 May 2023
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search